LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09044
Recombinant Monoclonal Antibody
Key Product Details
Species Reactivity
Mouse
Applications
Block/Neutralize, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # C9B7W
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
This antibody was raised by immunising Lewis rats with a murine LAG-3:Ig fusion protein.
Specificity
This antibody is specific for an epitope in the D2 domain of murine LAG-3.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Scientific Data Images for LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free
Immunocytochemistry/ Immunofluorescence: LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free [NBP3-09044]
Immunocytochemistry/Immunofluorescence: LAG-3 Antibody (C9B7W) - Chimeric [NBP3-09044] - Immunofluorescence analysis of paraformaldehyde fixed mouse splenocytes immobilized on Shi-fix(TM) cover-slips and stained with the chimeric rabbit IgG version of C9B7W (NBP3-09044) at 10 ug/ml followed by Alexa Fluor(R) 488 secondary antibody (2 ug/ml), showing membrane staining in subset of cells. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP3-09044, DAPI, merged channels and an isotype control. The isotype control was stained with anti-Fluorescein antibody followed by Alexa Fluor(R) 488 secondary antibody.ELISA: LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free [NBP3-09044] -
ELISA: LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free [NBP3-09044] - ELISA Plate coated with recombinant mouse LAG-3 Fc-Fusion Protein at a concentration of 2 ug/ml. A 4-fold serial dilution from 5,000 ng/ml was performed using NBP3-09044. For detection, a 1:4000 dilution of HRP-labelled anti-rabbit antibody was used.Applications for LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free
Application
Recommended Usage
Block/Neutralize
Optimal dilutions of this antibody should be experimentally determined.
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.
This antibody has been used in flow cytometric analysis of splenocytes (Workman et al, 2005), T cell hybridomas expressing wild-type or chimeric CD4: murine LAG-3 (Workman et al, 2002) and CD4 positive regulatory T cells (Chien et al, 2017). It has also been used in immunoprecipitation analysis of murine T hybridoma 3A9 cells transduced with murine LAG-3 (Li et al, 2004). This antibody blocks LAG-3 function in vitro, inhibiting antigen-induced IL-2 production in LAG-3-expressing T cell hybridomas, but does not block LAG-3: MHC class II interaction (Workman et al, 2002). Treatment with this antibody also blocks LAG-3 function in vivo, leading to accelerated homeostatic expansion of WT T cells (Workman et al, 2005). Administration of this LAG-3-blocking antibody, in combination with PD-L1 blockade, synergistically improves the survival of lymphodepleted myeloma-bearing mice (Jing et al, 2015).
This antibody has been used in flow cytometric analysis of splenocytes (Workman et al, 2005), T cell hybridomas expressing wild-type or chimeric CD4: murine LAG-3 (Workman et al, 2002) and CD4 positive regulatory T cells (Chien et al, 2017). It has also been used in immunoprecipitation analysis of murine T hybridoma 3A9 cells transduced with murine LAG-3 (Li et al, 2004). This antibody blocks LAG-3 function in vitro, inhibiting antigen-induced IL-2 production in LAG-3-expressing T cell hybridomas, but does not block LAG-3: MHC class II interaction (Workman et al, 2002). Treatment with this antibody also blocks LAG-3 function in vivo, leading to accelerated homeostatic expansion of WT T cells (Workman et al, 2005). Administration of this LAG-3-blocking antibody, in combination with PD-L1 blockade, synergistically improves the survival of lymphodepleted myeloma-bearing mice (Jing et al, 2015).
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
0.02% Proclin 300
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: LAG-3
As mentioned above, LAG-3 binds to MHCII and this occurs via a proline-rich amino acid loop in D1 (1, 3). Another unique feature of LAG-3 is the longer connecting peptide region between the D4 and the transmembrane, which is acted upon and cleaved by metalloproteinases a disintegrin and metallopeptidase domain (ADAM) 10 and ADAM17 to generate a soluble 54 kDa form of LAG-3 (sLAG-3) (1, 3). The interaction of LAG-3 with MHCII prevents the MHC molecule from binding to a T-cell receptor (TCR) or CD4, thereby functioning in an inhibitory role and suppressing the TCR signal (4). When LAG-3 crosslinks with the TCR/CD3 complex, it causes reduced T-cell proliferation and cytokine secretion (4). This negative regulation is important in controlling autoimmunity as one study found Lag3-/- NOD (non-obese diabetic) mice had accelerated diabetes onset and increased T-cell infiltration into islet cells (5). On the other hand, besides being a negative regulator of T-cells, LAG-3 binding to MHCII molecules on APCs induces dendritic cell maturation and cytokine secretion by monocytes (5, 6). In addition to MHCII, other reported ligands for LAG-3 includes fibrinogen-like protein 1 (FGL1), liver endothelial cell lectin (lSECtin), galectin-3 (Gal-3), and alpha-synuclein fibrils (1). Gal-3, for instance, is expressed on stromal cells and CD8+ T-cells in the tumor microenvironment and the interaction with LAG-3 was shown to be crucial for the suppression of secreted cytokine IFN-gamma and may control anti-tumor immune responses (1, 5). Interestingly, a mouse model of Parkinson's disease revealed LAG-3 binding to alpha-synuclein fibrils in the central nervous system, contributing to its pathogenesis (1, 5).
Recent cancer immunotherapeutic approaches have focused on inhibitory receptors such as LAG-3 to revive expression of cytotoxic T-cells to attack tumors (6). LAG-3 has been shown to be co-expressed and have synergy with another immune-checkpoint molecule called programmed-death 1 (PD-1) (1, 4, 5, 6). In a mouse model of colon adenocarcinoma LAG3 blockade alone was largely ineffective, however co-blockade of LAG-3 and PD-1 limited tumor growth and resulted in tumor clearance in 80% of mice, compared to 40% with PD-1 blockade alone (5). Additionally, in a model of fibrosarcoma the LAG-3/PD-1 duel blockade increased survival and the percentage of tumor-free mice (5). Analysis of a variety of human tumor samples (e.g. melanoma, colon cancer, head and neck squamous cell carcinoma) also suggest that LAG3 alone and combinatorial treatment with PD-1 may be a good target for treatment (1, 3-6). To date there are over 10 different agents targeting LAG-3 in clinical trials for cancer either as an anti-LAG-3 blocking antibody monotherapy or as a combination antagonist bispecific antibody, primarily with PD-1 (1, 3-6).
Alternative names for LAG-3 includes 17b4 lag3, 17b4 neutralizing, 17b4, CD223, FDC, LAG-3 17b4, LAG-3 blocking, and LAG3.
References
1. Maruhashi, T., Sugiura, D., Okazaki, I. M., & Okazaki, T. (2020). LAG-3: from molecular functions to clinical applications. Journal for Immunotherapy of Cancer, 8(2), e001014. https://doi.org/10.1136/jitc-2020-001014
2. Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990). LAG-3, a novel lymphocyte activation gene closely related to CD4. The Journal of experimental medicine, 171(5), 1393-1405. https://doi.org/10.1084/jem.171.5.1393
3. Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. (2019). Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Seminars in immunology, 42, 101305. https://doi.org/10.1016/j.smim.2019.101305
4. Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018). The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes & cancer, 9(5-6), 176-189.
5. Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. (2017). LAG3 (CD223) as a cancer immunotherapy target. Immunological reviews, 276(1), 80-96. https://doi.org/10.1111/imr.12519
6. Goldberg, M. V., & Drake, C. G. (2011). LAG-3 in Cancer Immunotherapy. Current topics in microbiology and immunology, 344, 269-278. https://doi.org/10.1007/82_2010_114
Long Name
Lymphocyte-activation Gene 3
Alternate Names
CD223, LAG3
Gene Symbol
LAG3
Additional LAG-3 Products
Product Documents for LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free
Product Specific Notices for LAG-3 Antibody (C9B7W) - Chimeric - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...